Latest

1 story

Hide weekly roundups

Thursday, September 24

Alveus registers Phase 2 trial of ALV-100 for weight-loss maintenance after semaglutide

Trial updateAlveus Therapeutics, Inc semaglutide

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.